STAR-CAP临床预后系统在欧洲根治性前列腺切除队列中的验证
Kaplan-Meier分析显示各分期组间分层良好(p < 0.001),10年预测生化复发、转移和肿瘤特异性死亡的AUC分别为0.73、0.84和0.75,验证了STAR-CAP在欧洲根治性前列腺切除人群中的预测性能。
要点
- STAR-CAP可对根治性前列腺切除术后各分期组进行良好的生存分层(组间p < 0.001)。
- 10年预测转移的AUC为0.84,区分能力优于生化复发(0.73)和肿瘤特异性死亡(0.75)。
- 该工具可用于欧洲前列腺癌患者根治性前列腺切除术前的咨询与预后评估。
核心结论
- STAR-CAP临床预后系统在欧洲接受根治性前列腺切除术的患者中验证有效,能较好预测生化复发、转移和肿瘤特异性死亡。
研究设计与样本
- 评估10年生化复发无生存、无转移生存和肿瘤特异性生存,计算AUC并进行决策曲线分析。
主要发现
- Kaplan-Meier分析显示STAR-CAP对各分期组的生化复发无生存、无转移生存和肿瘤特异性生存分层良好(组间p < 0.001)。
- 10年预测生化复发、转移和肿瘤特异性死亡的AUC分别为0.73、0.84和0.75。
关键数值与推荐
- STAR-CAP分期从IA(最低风险)至IIIC(最高风险),依据STAR-CAP评分标准计算总分划分。
- 10年预测生化复发、转移、肿瘤特异性死亡的AUC分别为0.73、0.84、0.75。
临床怎么用
- 可用于根治性前列腺切除术前向患者咨询预后,按STAR-CAP分期评估生化复发、转移和肿瘤特异性死亡风险。
局限性
- 为单中心回顾性研究,数据来自单一机构数据库,未报告外部多中心验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The proposed international staging collaboration for cancer of the prostate (STAR-CAP) clinical prognostic system for prostate cancer predicts cancer-specific mortality (CSM) for patients for whom active treatment, such as radical prostatectomy (RP), is planned. Until now, no validation of STAR-CAP has been performed. We retrospectively analyzed data from our institutional database for 19 552 patients treated with RP between 1992 and 2015. We applied the STAR-CAP point assignment criteria to calculate total individual scores and then classified patients according to the STAR-CAP stage groups ranging from IA (lowest risk) to IIIC (highest risk). We evaluated biochemical recurrence (BCR)-free survival, metastasis-free survival (MFS), and cancer-specific survival (CSS) stratified by STAR-CAP stage groups over 10 yr, calculated the area under the receiver operating characteristics curve (AUC), and performed decision curve analyses to assess the ability of STAR-CAP to predict these outcomes after fitting the data from our single-institution data set. STAR-CAP performed well in stratifying individual survival outcomes for BCR-free survival, MFS, and CSS for each stage group in Kaplan-Meier analyses (p < 0.001 between groups). The AUC for prediction of BCR, metastasis, and CSM at 10 yr was 0.73, 0.84, and 0.75, respectively. Our findings validate the performance of STAR-CAP for European patients treated with RP. PATIENT SUMMARY: We validated the STAR-CAP system for predicting cancer outcomes after removal of the prostate. Our results show that the system performs well and could help in counseling patients with prostate cancer.
引用
- Würnschimmel C, Pose RM, Wenzel M, et al. Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort. Eur Urol. 2021. PMID: 34162491. doi:10.1016/j.eururo.2021.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。